Nasopharyngeal carcinoma burden in the United States and worldwide, 1990 to 2023: A pairwise analysis with mortality projections to 2050.
13 affiliations
- 1Dermatology Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
- 2Ministry of Health, Saudi Arabia.
- 3College of Medicine, Qassim University, Qassim, Saudi Arabia.
- 4Royal College of Surgeons in Ireland, Dublin, Ireland.
- 5Najran University, Najran City, Saudi Arabia.
- 6College of Medicine and Surgery, Taif University, Taif, Saudi Arabia.
- 7Batterjee Medical College, Aseer, Saudi Arabia.
- 8College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- 9College of Medicine, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.
- 10University of Szeged Albert Szent-Györgyi, Szeged, Hungary.
- 11Arabian Gulf University, Bahrain.
- 12Faculty of Medicine, Lebanese University, Beirut, Lebanon.
- 13King Fahad Specialist Hospital, Tabuk Health Cluster, Tabuk, Saudi Arabia.
Abstract
Nasopharyngeal carcinoma (NPC) is a rare but geographically concentrated malignancy. Long-term comparative analyses of NPC trends between the United States and global populations, particularly by sex, are limited. Using Global Burden of Disease 2023 data, we analyzed temporal trends in NPC incidence, prevalence, and mortality from 1990 to 2023 in the United States and worldwide. Age-standardized rates per 100,000 population were calculated. Joinpoint regression estimated annual percent changes (APCs) and average annual percent change (AAPC) with 95% confidence intervals. Pairwise comparisons assessed differences between United States and global trends. Mortality forecasts through 2050 were generated using the established Global Burden of Disease forecasting framework. From 1990 to 2023, US age-standardized mortality declined by 44%, from 0.34 to 0.19 per 100,000 (AAPC: -1.70), while global mortality decreased from 1.46 to 0.83 (AAPC: -1.70). Global mortality increased between 2020 and 2023 (APC: 2.06), unlike the US decline. The incidence rate declined in the United States over the study period (AAPC: -1.03), while remaining largely stable globally. However, global incidence increased between 2020 and 2023 (APC: 3.86). Similarly, prevalence decreased in the United States (AAPC: -0.81) while showing a rising trend worldwide (AAPC: 0.74). Males consistently exhibited higher rates across all measures. Pairwise comparisons showed significant differences between United States and global trends. From 2023 to 2050, global NPC age-standardized mortality rate is projected to increase by 12.05% (0.93, 95% uncertainty interval [UI]: 0.75-1.16), driven by a 21.8% rise in males (1.45, 95% UI: 1.18-1.78), while declining by 11.76% in females (0.45, 95% UI: 0.33-0.63). In the United States, age-standardized mortality rate is projected to increase by 10.5% (0.21, 95% UI: 0.18-0.23), with a 17.9% rise in males (0.33, 95% UI: 0.29-0.37) and an 11.82% decline in females (0.097, 95% UI: 0.08-0.12). US NPC burden has declined steadily, while global patterns show rising prevalence and recent mortality increases. The observed differences in burden and temporal trends underscore the importance of further research into strategies for surveillance, early detection, and prevention in high-risk populations.
Related
- Trends and projections of colorectal carcinoma mortality in U.S. adults, 1999-2050: A CDC WONDER-based ecological time-series analysis.
- Primary Epstein–Barr virus-negative lymphoepithelioma-like carcinoma of the supraglottic larynx mimicking nasopharyngeal carcinoma: a case report
- The association between serum uric acid and prognosis of nasopharyngeal carcinoma: a comprehensive meta-analysis of observational studies
- Nasopharyngeal Carcinoma Mimicking Juvenile Nasopharyngeal Angiofibroma in an Adolescent Ghanaian Male: A Diagnostic Pitfall.
- Epstein-Barr virus co-opts ADAR1 to evade PKR activation of the integrated stress response in nasopharyngeal carcinoma
BibTeX
@article{altamimi2026nasopharyngeal,
title = {{Nasopharyngeal carcinoma burden in the United States and worldwide, 1990 to 2023: A pairwise analysis with mortality projections to 2050.}},
author = {Ibraheem Altamimi and Zainab Yunus Alfallatah and Abdulrahman Alzmmam and Mesfer Alsaqoor and Mohammed Ibrahim A Almakrami and Abdulaziz Abdulmalik Althubyani and Mubarak Mohammed Alshahrani and Abdulmalik Abdulelah Bin Kassim and Mohammed Abdullah Alharbi and Muath Hamad Alqesair and Mohammed Adel Albalawi and Aalaa Saleh and Saad Hamdi Alenzi},
journal = {Medicine},
year = {2026},
month = oct,
doi = {10.1097/md.0000000000051132},
url = {https://europepmc.org/article/MED/42888609},
note = {CC BY},
}
RIS
TY - JOUR
TI - Nasopharyngeal carcinoma burden in the United States and worldwide, 1990 to 2023: A pairwise analysis with mortality projections to 2050.
AU - Ibraheem Altamimi
AU - Zainab Yunus Alfallatah
AU - Abdulrahman Alzmmam
AU - Mesfer Alsaqoor
AU - Mohammed Ibrahim A Almakrami
AU - Abdulaziz Abdulmalik Althubyani
AU - Mubarak Mohammed Alshahrani
AU - Abdulmalik Abdulelah Bin Kassim
AU - Mohammed Abdullah Alharbi
AU - Muath Hamad Alqesair
AU - Mohammed Adel Albalawi
AU - Aalaa Saleh
AU - Saad Hamdi Alenzi
PY - 2026
DA - 2026/10/01
JO - Medicine
DO - 10.1097/md.0000000000051132
UR - https://europepmc.org/article/MED/42888609
AB - Nasopharyngeal carcinoma (NPC) is a rare but geographically concentrated malignancy. Long-term comparative analyses of NPC trends between the United States and global populations, particularly by sex, are limited. Using Global Burden of Disease 2023 data, we analyzed temporal trends in NPC incidence, prevalence, and mortality from 1990 to 2023 in the United States and worldwide. Age-standardized rates per 100,000 population were calculated. Joinpoint regression estimated annual percent changes (APCs) and average annual percent change (AAPC) with 95% confidence intervals. Pairwise comparisons assessed differences between United States and global trends. Mortality forecasts through 2050 were generated using the established Global Burden of Disease forecasting framework. From 1990 to 2023, US age-standardized mortality declined by 44%, from 0.34 to 0.19 per 100,000 (AAPC: -1.70), while global mortality decreased from 1.46 to 0.83 (AAPC: -1.70). Global mortality increased between 2020 and 2023 (APC: 2.06), unlike the US decline. The incidence rate declined in the United States over the study period (AAPC: -1.03), while remaining largely stable globally. However, global incidence increased between 2020 and 2023 (APC: 3.86). Similarly, prevalence decreased in the United States (AAPC: -0.81) while showing a rising trend worldwide (AAPC: 0.74). Males consistently exhibited higher rates across all measures. Pairwise comparisons showed significant differences between United States and global trends. From 2023 to 2050, global NPC age-standardized mortality rate is projected to increase by 12.05% (0.93, 95% uncertainty interval [UI]: 0.75-1.16), driven by a 21.8% rise in males (1.45, 95% UI: 1.18-1.78), while declining by 11.76% in females (0.45, 95% UI: 0.33-0.63). In the United States, age-standardized mortality rate is projected to increase by 10.5% (0.21, 95% UI: 0.18-0.23), with a 17.9% rise in males (0.33, 95% UI: 0.29-0.37) and an 11.82% decline in females (0.097, 95% UI: 0.08-0.12). US NPC burden has declined steadily, while global patterns show rising prevalence and recent mortality increases. The observed differences in burden and temporal trends underscore the importance of further research into strategies for surveillance, early detection, and prevention in high-risk populations.
SN - 0304-5412
SN - 1536-5964
ER -